FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888482918> ?p ?o ?g. }

• W2888482918 abstract "Background: It has been demonstrated in various studies that ADMA (asymmetric dimethylarginine), an inhibitor of nitric oxide synthase, is associated with the increased risk of cardiovascular diseases. There are two known pathways of ADMA metabolism: hydrolysis to citrulline by dimethylarginine dimethylaminohydrolases (DDAH) and transamination by alanine-glyoxylate aminotransferase 2 (AGXT2) with formation of asymmetric dimethylguanidino valeric acid (ADGV). The second pathway is still poorly understood. The goal of the current study was to test the hypothesis that transgenic overexpression of AGXT2 leads to lowering of plasma levels of ADMA and improvement of vasomotor function. Methods and Results: We generated transgenic mice (TG) with ubiquitous overexpression of AGXT2 under control of the chicken beta actin (CAG) promoter. qPCR and Western Blot were used to confirm the ubiquitous expression of the transgene. HPLC-MS/MS was used to generate biochemical data. Systemic ADMA levels were decreased by 15% (p<0.05) in the TG mice, whereas ADGV plasma levels were six times higher in comparison with wild type animals (p<0.001). Heart and lung of TG animals exhibited 2 times lower tissue ADMA content in comparison with wild type littermates (p<0.05). In further experiments, we crossed the AGXT2 TG mice with DDAH1 KO mice and showed that upregulation of AGXT2 protects DDAH1 KO mice from elevation of plasma ADMA levels and restores endothelium-dependent vasodilation in aortic rings. In the current experiments we are assessing whether AGXT2 overexpression also protects DDAH1 KO mice from hypertension. Conclusion: In the current study we demonstrated that upregulation of AGXT2 leads to lowering of ADMA levels and improvement of endothelium-dependent relaxation in vivo in the settings of DDAH1 deficiency . AGXT2 thereby may be a potential drug target for long-term reduction of systemic ADMA levels in cardiovascular pathologies. This is especially important, because all the efforts to develop pharmacological ADMA-lowering interventions by means of upregulation of DDAH have not been successful so far." @default.
• W2888482918 created "2018-08-31" @default.
• W2888482918 creator A5004322058 @default.
• W2888482918 creator A5008155631 @default.
• W2888482918 creator A5011448945 @default.
• W2888482918 creator A5016795540 @default.
• W2888482918 creator A5019250344 @default.
• W2888482918 creator A5034627046 @default.
• W2888482918 creator A5036984095 @default.
• W2888482918 creator A5040932572 @default.
• W2888482918 creator A5043558247 @default.
• W2888482918 creator A5053809003 @default.
• W2888482918 creator A5053956338 @default.
• W2888482918 creator A5054226568 @default.
• W2888482918 creator A5061182191 @default.
• W2888482918 creator A5067586270 @default.
• W2888482918 creator A5080157679 @default.
• W2888482918 creator A5087167001 @default.
• W2888482918 creator A5090173785 @default.
• W2888482918 date "2017-05-01" @default.
• W2888482918 modified "2023-09-27" @default.
• W2888482918 title "Abstract 185: Transgenic Overexpression of Alanine-glyoxylate Aminotransferase 2 in Mice Lowers Asymmetric Dimethylarginine and Improves Vasomotor Function" @default.
• W2888482918 doi "https://doi.org/10.1161/atvb.37.suppl_1.185" @default.
• W2888482918 hasPublicationYear "2017" @default.
• W2888482918 type Work @default.
• W2888482918 sameAs 2888482918 @default.
• W2888482918 citedByCount "0" @default.
• W2888482918 crossrefType "journal-article" @default.
• W2888482918 hasAuthorship W2888482918A5004322058 @default.
• W2888482918 hasAuthorship W2888482918A5008155631 @default.
• W2888482918 hasAuthorship W2888482918A5011448945 @default.
• W2888482918 hasAuthorship W2888482918A5016795540 @default.
• W2888482918 hasAuthorship W2888482918A5019250344 @default.
• W2888482918 hasAuthorship W2888482918A5034627046 @default.
• W2888482918 hasAuthorship W2888482918A5036984095 @default.
• W2888482918 hasAuthorship W2888482918A5040932572 @default.
• W2888482918 hasAuthorship W2888482918A5043558247 @default.
• W2888482918 hasAuthorship W2888482918A5053809003 @default.
• W2888482918 hasAuthorship W2888482918A5053956338 @default.
• W2888482918 hasAuthorship W2888482918A5054226568 @default.
• W2888482918 hasAuthorship W2888482918A5061182191 @default.
• W2888482918 hasAuthorship W2888482918A5067586270 @default.
• W2888482918 hasAuthorship W2888482918A5080157679 @default.
• W2888482918 hasAuthorship W2888482918A5087167001 @default.
• W2888482918 hasAuthorship W2888482918A5090173785 @default.
• W2888482918 hasConcept C102230213 @default.
• W2888482918 hasConcept C104317684 @default.
• W2888482918 hasConcept C126322002 @default.
• W2888482918 hasConcept C127561419 @default.
• W2888482918 hasConcept C134018914 @default.
• W2888482918 hasConcept C141035611 @default.
• W2888482918 hasConcept C185592680 @default.
• W2888482918 hasConcept C2776415932 @default.
• W2888482918 hasConcept C2777468819 @default.
• W2888482918 hasConcept C2777622882 @default.
• W2888482918 hasConcept C2779856020 @default.
• W2888482918 hasConcept C2779877776 @default.
• W2888482918 hasConcept C515207424 @default.
• W2888482918 hasConcept C519581460 @default.
• W2888482918 hasConcept C55493867 @default.
• W2888482918 hasConcept C71924100 @default.
• W2888482918 hasConceptScore W2888482918C102230213 @default.
• W2888482918 hasConceptScore W2888482918C104317684 @default.
• W2888482918 hasConceptScore W2888482918C126322002 @default.
• W2888482918 hasConceptScore W2888482918C127561419 @default.
• W2888482918 hasConceptScore W2888482918C134018914 @default.
• W2888482918 hasConceptScore W2888482918C141035611 @default.
• W2888482918 hasConceptScore W2888482918C185592680 @default.
• W2888482918 hasConceptScore W2888482918C2776415932 @default.
• W2888482918 hasConceptScore W2888482918C2777468819 @default.
• W2888482918 hasConceptScore W2888482918C2777622882 @default.
• W2888482918 hasConceptScore W2888482918C2779856020 @default.
• W2888482918 hasConceptScore W2888482918C2779877776 @default.
• W2888482918 hasConceptScore W2888482918C515207424 @default.
• W2888482918 hasConceptScore W2888482918C519581460 @default.
• W2888482918 hasConceptScore W2888482918C55493867 @default.
• W2888482918 hasConceptScore W2888482918C71924100 @default.
• W2888482918 hasIssue "suppl_1" @default.
• W2888482918 hasLocation W28884829181 @default.
• W2888482918 hasOpenAccess W2888482918 @default.
• W2888482918 hasPrimaryLocation W28884829181 @default.
• W2888482918 hasRelatedWork W1995502540 @default.
• W2888482918 hasRelatedWork W2018690794 @default.
• W2888482918 hasRelatedWork W2024618244 @default.
• W2888482918 hasRelatedWork W2095483432 @default.
• W2888482918 hasRelatedWork W2104791454 @default.
• W2888482918 hasRelatedWork W2122395778 @default.
• W2888482918 hasRelatedWork W2151554519 @default.
• W2888482918 hasRelatedWork W2153125904 @default.
• W2888482918 hasRelatedWork W4248381333 @default.
• W2888482918 hasRelatedWork W917399764 @default.
• W2888482918 hasVolume "37" @default.
• W2888482918 isParatext "false" @default.
• W2888482918 isRetracted "false" @default.
• W2888482918 magId "2888482918" @default.
• W2888482918 workType "article" @default.